Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.

Latest Cases

A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Research Legacy
Research Legacy contains a graphic display of a few of the companies’ stock performances that are included in the Complete Investment Record section. All of the information contained here is selected to highlight Asensio & Company’s most dramatic and successful investments. The graphs were selected from among those companies where Asensio & Company was most actively involved and it had a concentrated position and well-publicized document record. The statements selected to accompany the graphs leave no doubt about Asensio & Company’s position with regards to its opinion about the company’s stock value.

Readers are referred to the "Our Track Record" section for more accurate information about the prices and dates contained on the graphs in this section.


Zonagen (ZONA)
Zonagen is by all economic and financial measures grossly overvalued. We believe that this is a result of Zonagen's high selective disclosures concerning its Vasomax test results, promotion of its future prospects and failure to disclose material negative information. We believe that Zonagen's management has consistently misled investors about Vasomx's NDA filing deadlines, product efficacy and patent position. We see no possible realistic outcome that can justify Zonagen's current stock price.
Solv-Ex Corporation (SOLVQ)
Solv-Ex's plant is ill-designed and will not produce bitumen. Management is corrupt. We believe Solv-Ex's shares will soon be worthless.
ErgoBilt, Inc. (ERGBE)
Contrary to management claims, Ergobilt's Fon'iks Writer is nothing new. In fact, it is digitext that has already been used by a new defunct stock promotion.
SyQuest Technology, Inc. (SYQT)
We believe that Syquest's ability to remain in business is a far truer concern than whether its stock is nearly its current price. We further believe that the Company is most likely worth less than its liabilities, and that current equity holders will suffer significant dilution even if distress financing is made available.
Crystallex International (KRY)
Copy to be provided.
Able Telecom Holding Corp. (ABTE)
Investors may be buying Able shares believing that its recently acquired MFS Network Technologies subsidiary ("NT") possesses some value in excess of Able's purchase cost. In fact, some investors have no information concerning Able capital structure after the NT acquisition. Any information to the contrary is false and misleading.
Turbodyne Technologies (TRBDF)
Turbodyne Technologies electric supercharger is an absurd product with little or no sales potential.
Verisign (VRSN)
Copy to be provided.
Research Frontiers (REFR)
Copy to be provided.
Winstar (WRL)
Copy to be provided.
The Diana Corporation (DNA)
Many of Diana's product claims are false. Diana possesses no valuable technology. Its shares are grossly overvalued. We believe they will quickly give-back all of their gains.
Brocade (BRCD)
Copy to be provided.
Cellular Technical Services
Company, Inc. (CTSC)
CTSC's situation is more a challenge to remain solvent rather than an opportunity to increase its already staggering $380 million market value. We see no possible future outcome that can remotely justify CTSC's current market value. We believe the shares would be overvalued at half their price.
Hemispherx Biopharma (HEB) Copy to be provided.
Hemispherx Biopharma (HEB) Copy to be provided.
Multimedia Games (MGAM)
Copy to be provided.
 
[ Back ]
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
© 2009 Asensioexposes!com offers accurate facts that disproves past criticism of the Manuel Asensio Reports. Web Directory
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.